Want to see TSE:XRTX full AI Analyst Report?
XRTX Stock Chart & Stats
C$0.78
C$0.05(2.94%)
At close: 4:00 PM EST
C$0.78
C$0.05(2.94%)
Day’s Range― - ―
52-Week RangeC$2.43 - C$9.85
Previous CloseN/A
Volume514.00
Average Volume (3M)11.08K
Market Cap
C$5.54M
Enterprise ValueC$363.24K
Total Cash (Recent Filing)C$250.45K
Total Debt (Recent Filing)C$15.07K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,730,565
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)C$3.25M
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company's negligible reported debt and very low debt-to-equity ratio materially reduce financial distress risk for a clinical-stage biotech. This structural balance sheet strength gives management flexibility to time financing, limits cash interest burden, and preserves capacity to fund R&D or seek partnerships without immediate leverage constraints.
Improving Loss TrajectoryA marked narrowing of operating losses versus 2022 indicates durable progress toward expense control and program prioritization. Sustained improvement in losses reduces near-term funding pressure, improves prospects for extending operational runway, and signals management execution that can support continued program advancement and partner interest.
Focused Clinical-stage PipelineA concentrated pipeline targeting uric-acid control and kidney disease establishes a clear strategic specialization. This focused therapeutic niche can create durable competitive differentiation, streamline R&D prioritization, and make the company an attractive partner or acquisition target for larger firms seeking renal/metabolic assets and expertise.
Bears Say
No Revenue And Persistent Net LossesAs a development-stage biotech, absence of product revenue and recurring net losses mean the company cannot self-fund operations. This structural dependency on external capital increases dilution and execution risk, and constrains the firm’s ability to independently advance multiple clinical programs over the medium term.
Shrinking Equity BaseA materially reduced equity base signals accumulated losses and/or prior dilution, weakening the capital cushion that absorbs setbacks. This structural erosion raises the likelihood that future financing will be dilutive or costly, and reduces the firm's resilience to clinical or regulatory setbacks without rapid access to new funding.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow, with recent FCF contraction, demonstrates the company lacks internal cash generation to sustain development. Over a multi-month horizon, this persistent burn necessitates additional capital raises, creating execution risk for clinical programs and potentially delaying milestone-driven value creation.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$2.42 and its highest was C$9.85 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$5.54M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 42 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -C$0.824 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.824.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,730,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.824 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20.288%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---